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Background Epidemiologic data suggests that only a minority of tuberculosis (TB) patients are infectious. Cough aerosol sam-
pling is a novel quantitative method to measure TB infectiousness. 
Methods We analyzed data from three studies conducted in Uganda and Brazil over a 13-year period. We included sputum acid 
fast bacilli (AFB) and culture positive pulmonary TB patients and used a cough aerosol sampling system (CASS) to measure the 
number of colony-forming units (CFU) of Mycobacterium tuberculosis in cough-generated aerosols as a measure for infectiousness. 
Aerosol data was categorized as: aerosol negative (CFU = 0) and aerosol positive (CFU > 0). Logistic regression models were built to 
identify factors associated with aerosol positivity.
Results M. tuberculosis was isolated by culture from cough aerosols in 100/233 (43%) TB patients. In an unadjusted analysis, 
aerosol positivity was associated with fewer days of antituberculous therapy before CASS sampling (p = .0001), higher sputum AFB 
smear grade (p = .01), shorter days to positivity in liquid culture media (p = .02), and larger sputum volume (p = .03). In an adjusted 
analysis, only fewer days of TB treatment (OR 1.47 per 1 day of therapy, 95% CI 1.16-1.89; p = .001) was associated with aerosol 
positivity.
Conclusion Cough generated aerosols containing viable M. tuberculosis, the infectious moiety in TB, are detected in a minority 
of TB patients and rapidly become non-culturable after initiation of antituberculous treatment. Mechanistic studies are needed to 
further elucidate these findings.
Globally, tuberculosis disease is the leading cause of infectious 
disease mortality with an estimated 10 million new cases and 
1.6 million deaths in 2017 [1]. The End TB strategy by the 
World Health Organization suggests diminishing the large 
reservoir of latent tuberculosis infection, because providing 
therapy only for active tuberculosis would not meet the in-
tended target of decreasing incidence by 15%–20% per year 
[2]. In settings with a high incidence of tuberculosis, most 
cases of tuberculosis disease occur after recent transmission, 
rather than reactivation from old exposures [3]. In this con-
text, interventions aimed at preventing new infections and 
targeting preventive therapy to those at highest risk of pro-
gression to tuberculosis disease are likely to have the most 
significant effect on lowering incidence [4, 5].
Despite recent advances in the fields of tuberculosis 
diagnostics and treatment, knowledge about host and bacte-
rial factors leading to successful person-to-person transmis-
sion of Mycobacterium tuberculosis remain largely unknown. 
A  central observation in this field was established by Riley 
and colleagues in the 1950s [6] when they conclusively 
demonstrated that tuberculosis is transmitted by fine aerosols 
[7, 8]. However, abundant epidemiological data have since 
shown marked variability in tuberculosis transmission, with 
most secondary infections and disease cases clustered around 
a minority of pulmonary tuberculosis cases [9, 10]. One dif-
ficulty in studying the mechanisms modulating tuberculosis 
transmission has been the inability to collect and quantify 
airborne M. tuberculosis. Instead, most of the published liter-
ature on tuberculosis transmission has used visualization and 
density of acid-fast bacilli (AFB) in expectorated sputum, a 
relatively easily obtained clinical specimen, as a surrogate for 
source infectiousness.
Since first demonstrating the feasibility of culturing M. tu-
berculosis directly from cough-generated aerosol samples in 
2004 [10], our group has completed several studies showing 
that the number of colony-forming units (CFUs) of M. tuber-
culosis in aerosol samples is a quantitative and more precise 
marker of infectiousness than sputum AFB smear [11–13], 
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and have demonstrated reproducibility [14]. In studies from 
Uganda and Brazil, household contacts of the minority of tu-
berculosis cases with high aerosol CFU counts (≥10 CFUs) 
were found to have both a higher risk of infection—as meas-
ured by qualitative and quantitative readouts of tuberculin 
skin test and interferon gamma release assay—and higher 
rates of secondary tuberculosis disease during follow-up 
[13, 14]. Therefore, elucidating which host, environmental 
and bacterial factors are associated with M.  tuberculosis 
aerosolization will provide fundamental insights into the 
pathogen’s aerobiology and may lead to interventions to in-
terrupt transmission.
In our group’s initial study in Uganda [11], cough-
generated aerosol cultures of M.  tuberculosis were associ-
ated with the sputum appearing more salivary than purulent. 
Cough-generated aerosol cultures were also associated with 
bacillary load, most notably when the surrogate of faster 
growth in liquid culture medium was used. However, that 
study was limited by a modest sample size, a single study site, 
and a high rate of tuberculosis treatment before aerosol col-
lection. In the current aggregated data analysis, we evaluated 
clinical, radiographic, and microbiological information from 
sputum AFB and culture-positive pulmonary tuberculosis 
case patients in 3 separate cohorts to characterize host factors 




The present study included data from 3 cohorts of adult patients 
(aged ≥18  years) with pulmonary tuberculosis, cohorts with 
near-identical inclusion criteria. The studies were conducted in 
Uganda and Brazil over a 13-year period [11, 12, 14].
Study 1.
This longitudinal cohort study, conducted at the National 
Tuberculosis and Leprosy Program (NTLP) Chemotherapy 
Centre at Mulago Hospital in Kampala, Uganda, enrolled 
patients from November 2002 to December 2004. Patients with 
suspicion of pulmonary tuberculosis were enrolled, including 
112 with suspected tuberculosis, 101 (90%) with culture-proven 
tuberculosis, and 90 who were sputum AFB positive.
Study 2.
This prospective household contact study was conducted at 
the same NTLP clinic in Kampala, Uganda. From May 2009 
to January 2011, it enrolled 96 participants with sputum AFB-
positive, culture-proven pulmonary tuberculosis.
Study 3.
This prospective household contact study was conducted at 
the Núcleo de Doencas Infecciosas (NDI) in Vitória, Brazil, 
enrolling patients from April 2013 to June 2015. It included 48 
human immunodeficiency virus (HIV)–uninfected participants 
with sputum AFB-positive (2+ or 3+), culture-proven pulmo-
nary tuberculosis.
All 3 studies excluded patients whose medical conditions 
could be exacerbated by coughing, who were too ill to consent, 
or who could not follow the study protocol. When the studies 
were conducted, Uganda was a country with a high tuberculosis 
burden and an estimated annual tuberculosis incidence rate 
of 350 cases per 100 000 inhabitants, and 39% of tuberculosis 
case patients were HIV infected. The Mulago Hospital NTLP 
clinic treated 3500–4000 patients with tuberculosis every year, 
of whom approximately 65% were AFB positive and 10% were 
receiving retreatment [15]. Brazil is a country with moderate 
tuberculosis incidence. The NDI has organized a network of 
16 tuberculosis clinics in the metropolitan region of Vitória. In 
Espírito Santo, the tuberculosis incidence is 38 cases per 100 000 
inhabitants; the prevalence of HIV infection in the general pop-
ulation is <1%, and 7% in patients with tuberculosis [16]
Measurements
We recorded demographic, clinical and radiographic data in 
eligible tuberculosis case patients. HIV testing was offered to 
participants in the Ugandan studies, and CD4 cell counts were 
obtained in those with HIV infection. In Brazil, HIV testing 
was performed by the local health system. At least 3 sputum 
specimens were obtained for AFB smear and culture in solid 
media (Lowenstein-Jensen in studies 1 and 2, Ogawa-Kudow 
in study 3) and liquid media (BACTEC 460 in studies 1 and 2 
and mycobacteria growth indicator tube [MGIT] 960 in study 
3), as described elsewhere [12–14]. Sputum AFB smear micro-
scopic findings were graded as 1+, 2+, or 3+ according to the 
International Union Against Tuberculosis and Lung Disease 
classification [17]. 
Posteroanterior chest radiographs were obtained to assess the 
extent of disease (normal/minimal disease, moderate advanced 
disease, and far advanced disease), and record the presence of 
cavities (yes or no) [18]. Radiographs were interpreted by an 
experienced radiologist at each site. In studies 2 and 3, cough 
strength was measured using a visual analog cough scale, as re-
ported elsewhere [18]. Cough peak flow rates were measured 
using portable peak flow meters [19]. The highest of 3 measures 
was included in the analysis. The duration of antituberculous 
therapy was defined as the number of days the participant had 
received tuberculosis treatment before the cough aerosol sam-
pling system (CASS) procedure was conducted. All participants 
were referred to their respective national tuberculosis program 
to start tuberculosis treatment according to national guidelines.
Aerosol Collection Procedure
The 3 studies collected M. tuberculosis from cough-generated 
aerosol samples using the same version of the CASS apparatus 
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described elsewhere in detail [11]. The CASS study pro-
tocol was identical for the 3 cohorts, and aerosol studies 
were performed by technicians similarly trained by one of us 
(K. P.  F.), as described elsewhere [11]. Briefly, subjects were 
instructed to cough into the CASS mouthpiece as much and 
as frequently as was comfortable for two 5-minute sessions, 
separated by a rest of approximately 5 minutes. The technician 
subjectively assessed the cough strength as weak or strong. The 
CASS chamber was autoclaved, and other components were 
disinfected after each study. During each CASS study, the win-
dows in the study room were open, and a fan was used to direct 
airflow from behind the technician, past the subject, and out 
through the windows. All study personnel wore fit-tested N95 
respirators.
After study completion, the aerosol samplers were removed 
and transported to the respective laboratory (Makerere 
University in Uganda and NDI in Brazil), where they were 
unloaded within a biological safety cabinet. Plates were 
incubated at 37°C. In Uganda, plates were read at weeks 1, 3, 6, 
and 9 to record CFU counts of M. tuberculosis; in Brazil, plates 
were read weekly for 6 weeks. We used the 6-week CFU count 
as the outcome measure. The appearance of sputum specimens 
expectorated during aerosol studies was classified as purulent, 
mucopurulent, mucosalivary, salivary, or bloody by the mi-
crobiology technicians, according to international laboratory 
guidelines [20]. These data were dichotomized into 2 groups for 
this analysis: purulent/mucopurulent or salivary/mucosalivary, 
with 2 bloody specimens excluded.
Statistical Analysis
The primary study outcome was the cough-generated aerosol 
status of patients with tuberculosis. We categorized tuberculosis 
case patients as aerosol negative (0 CFUs) or aerosol positive 
(≥1 CFU). The exposure variables included baseline clinical, 
radiographic and microbiological data from tuberculosis case 
patients. We calculated descriptive statistics to identify clinical 
and demographic differences between study cohorts. To eval-
uate the effect of antituberculous therapy on cough-generated 
aerosol results, we excluded 8 patients with multidrug-resistant 
tuberculosis, because response to treatment in such patients is 
expected to be slower than in drug-susceptible tuberculosis. To 
identify factors associated with M. tuberculosis growth in aer-
osol cultures we used χ2 tests for categorical and Kruskal-Wallis 
tests for numerical variables. Variables with a P value <.1 in the 
bivariate analysis and those considered clinically important (eg, 
HIV status and the presence of cavities on chest radiographs) 
were included in a multivariable logistic regression model. All 
analyses were performed with Stata 14 software.
Ethics Statement
The studies were approved by the Makerere University Faculty of 
Medicine Research and Ethics Committee, the Uganda National 
Council for Science and Technology, the Comitê de Ética em 
Pesquisa do Centro de Ciências da Saúde–Universidade Federal 
do Espírito Santo, the Comissão Nacional de Ética em Pesquisa, 
and the institutional review boards of Boston University 
Medical Center and New Jersey Medical School–Rutgers 
University (formerly UMDNJ). We obtained written informed 
consent and assent in the preferred local language in accord-
ance with age-specific ethical guidelines.
RESULTS
Among the 3 study cohorts, 275 patients with pulmonary tuber-
culosis were initially considered eligible for inclusion into this 
study. Of these, 42 (15%) were excluded, mostly because they had 
negative sputum AFB smear (n = 14) or culture (n = 10) results 
(Figure 1). Thus, the present analysis included 233 sputum AFB-
positive, culture-positive tuberculosis cases. All the excluded 
patients with negative smear and culture sputum results also had 
negative culture results from cough-generated aerosol samples.
The baseline characteristics of the 3 cohorts by study site are 
shown in Table 1. Overall, patients were young (median age, 
30 years; interquartile range, 25–40 years), with a preponderance 
of male patients (65%), and most had a high bacillary burden, 
as indicated by AFB smear grade 3+ in 152 (65%) and far ad-
vanced disease on chest radiograph in 133 (63%) of 209 patients. 
Participants from the 2 Ugandan cohorts were more likely to be 
HIV infected, to have salivary sputum (P <  .001), and to have 
received more days of antituberculous therapy before the CASS 
procedure (P < .001). We show the correlation between aerosol 
CFU count and sputum AFB smear grade in Figure 2.
Culturable M. tuberculosis From Cough-Generated Aerosol Samples
Of the 233 participants, 100 (43%) had culturable M. tubercu-
losis from cough-generated aerosol samples, of whom 43 (18%) 
had low and 57 (24%) had high aerosol CFU counts (defined 
as 1–9 vs ≥10 CFUs). In an unadjusted analysis, aerosol posi-
tivity was associated with fewer days of antituberculous therapy 
before CASS sampling (P  <  .001), higher sputum AFB smear 
grade (P = .01), shorter time to positivity in liquid culture me-
dium (P = .02), and larger sputum volume (P = .03) (Table 2). 
In an adjusted analysis, only shorter duration of antituberculous 
therapy before CASS was associated with aerosol positivity 
(odds ratio [OR], 1.47 per day of therapy; 95% confidence in-
terval [CI] 1.16–1.89; P  =  .001) (Table 3). This association 
remained statistically significant (OR, 1.38 per day; 95% CI, 
1.05–1.82; P = .02) when the outcome variable was restricted to 
patients with high aerosol CFU counts. Cough generated aer-
osol production according to sputum AFB is shown in Table 4.
Effect of Antituberculous Treatment on Aerosol Results
Of 206 participants (88%) with available treatment informa-
tion, we cultured M.  tuberculosis from cough-generated aer-
osol samples in 9 of 43 (20%) with >2 days of antituberculous 
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therapy, 40 of 99 (40%) with 1–2 days of therapy, and 38 of 64 
(59%) with no treatment before collection of aerosol samples. 
When they were compared with those receiving >2 days of tu-
berculosis therapy, the OR for aerosol positivity was 2.56 (95% 
CI, 1.11–5.92; P = .03) for those with 1–2 days of therapy, and 
5.5 (2.3–13.4; P < .001) for those without treatment (Figure 3A). 
In contrast, the effect of antituberculous therapy on sputum 
AFB smear grade (Figure 3B; P = .1) or sputum culture results 
(100% remained culture positive) was not apparent.
Effect of HIV Infection on Aerosol Results
Of 217 (93%) participants with available information on HIV 
status, 64 (29%) were HIV infected. The proportions of HIV-
infected patients (24 of 64 [38%]; OR, 0.75; 95% CI, .41–1.36) 
and HIV-uninfected patients (68 of 153 [44%]) with culturable 
M.  tuberculosis in aerosol samples were similar (P  =  .35). 
Among 53 participants with available CD4 cell count informa-
tion, 16 (30%) had CD4 cell counts <100 cells/mm3.  Aerosol 
positivity was higher for those with CD4 cell counts >100 cells/
mm3 (17 of 37 [46%]) than for those with CD4 cell counts 
<100  cells/mm3 (2 of 16 [13%]; OR, 5.95; 95% CI, 1.06–33.3; 
P =  .02). Among aerosol-positive patients, the median (inter-
quartile range) CFU cell count for those who were HIV negative 
was 20 (5–52) CFUs, compared with 8 (2–16) CFUs for those 
with HIV infection.
DISCUSSION
In this aggregated data analysis of 233 sputum AFB-positive/
culture-positive pulmonary tuberculosis case patients from 3 
cohorts, 43% of participants had culturable M. tuberculosis from 
cough-generated aerosol samples, of whom only 25% had high 
aerosol CFU counts (>10 CFUs). Culturable M. tuberculosis was 
inversely associated with the duration of antituberculous therapy 
before aerosol collection, and only partially related to common 
markers of sputum bacillary burden. Thus, these data are con-
sistent with the findings of epidemiological studies showing an 
association between bacillary load and transmission; however 
we suggest that the sputum AFB smear result is best considered 
a risk factor for infectiousness, not the sine qua non for infec-
tiousness, as it is often considered. In addition, aerosol posi-
tivity was not related to cough severity, self-reported duration 
of symptoms, or other standard markers of infectiousness, such 
as presence of cavities or extent of disease on chest radiographs. 
The observation that only a minority of patients with tu-
berculosis generate culturable aerosol samples is striking and 
unlikely to be explained by an insensitive method of aerosol 
collection. Investigators studying 2 different cohorts from 
South Africa, using a modified CASS and a novel respiratory 
aerosol collection chamber, reported similar rates (23%–43%) 
of M. tuberculosis in aerosol samples from patients with pulmo-
nary tuberculosis [21, 22]. Based on our data linking culturable 
aerosol samples and risk of tuberculosis infection and disease 
[12–14] we posit that aerosol positivity represents a unique sub-
group of individuals with enhanced ability to expel culturable 
aerosolized M.  tuberculosis, who therefore could be acting as 
disease superspreaders [23]. A better understanding of host and 
bacterial factors associated with M. tuberculosis aerosolization 





Reasons for exclusion (n = 42):
AFB smear negative         (n = 14)
Culture negative               (n = 10)
Withdrew consent            (n = 7)
No CASS results               (n = 6)
Lost to follow-up              (n = 4)









Aerosol negative: n = 62 (69%)
Low aerosol CFU count: n = 12 (13%)
High aerosol CFU count: n = 16 (18%)
Aerosol negative: n = 52 (55%)
Low aerosol CFU count: n = 18 (19%)
High aerosol CFU count: n = 25 (26%)
Aerosol negative: n = 19 (40%)
Low aerosol CFU count: n = 13 (27%)
High aerosol CFU count: n = 16 (33%)
Figure 1. Study population and aerosol results in each participating cohort of pulmonary tuberculosis cases patients. Abbreviations: AFB, acid-fast bacilli; CASS, cough 
aerosol sampling system; HHCs, household contacts.
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immunology and bacterial aerobiology. Furthermore, timely 
identification of superspreaders would allow targeted LTBI 
strategies and more effective infection control interventions.
Some findings of our study are noteworthy. First, aerosol pos-
itivity was only partially related to commonly used measures of 




















Figure 2. Culturable Mycobacterium tuberculosis colony-forming unit (CFU) count from cough-generated aerosol samples and sputum acid-fast bacilli (AFB) smear grade.
Table 1. Characteristics of Study Participants by Site
Characteristic
Patients, No. (%)a
P ValueUganda (2002–2004) (n = 90) Uganda (2009–2011) (n = 95) Brazil (2013–2015) (n = 48)
Age, median (IQR), y 32 (27–39) 29 (23–40) 32 (23–45) .10
Sex     
 Male 67 (74) 48 (51) 36 (75) .001
 Female 23 (26) 47 (49) 12 (25)
HIV infection 43 (56) 21 (23) 0 <.001
Duration of symptoms, median (IQR), wk 12 (8–20) 12 (8–16) 12 (7–24) .74
Duration of antibiotic treatment, median (IQR), d 4 (3–5) 1 (1–2) 0 (0-0) <.001
Extent of disease on chest radiograph     
 Normal/minimal 8 (11) 8 (9) 3 (6) .41
 Moderate 15 (21) 30 (33) 12 (25)
 Far advanced 48 (68) 52 (58) 33 (69)
Cavitations 49 (69) 60 (67) 41 (85) .05
Sputum appearance     
 Salivary/mucosalivary 49 (68) 39 (41) 2 (4) <.001
 Purulent/mucopurulent 23 (32) 55 (59) 44 (96)
Sputum AFB smear grade     
 1+ 16 (18) 15 (16) 3 (6) .07
 2+ 24 (27) 14 (15) 9 (19)
 3+ 50 (56) 66 (69) 36 (75)
Time to sputum culture positivity,b median (IQR) d 7 (4–11) 6 (4–8) 5 (4–7) .09
Aerosol CFU count     
 Median (IQR) 0 (0–4) 0 (0–11) 2 (0–45) .003
 Mean (SD) 13.9 (75.6) 16.2 (49.5) 33.1 (65.2)
 Range 0–710 0–378 0–333
Aerosol negative 62 (69) 52 (55) 19 (40) .02
Aerosol positive    
 Low aerosol CFU count (1–9 CFUs) 12 (13) 18 (19) 13 (27)
 High aerosol CFU count (≥10 CFUs) 16 (18) 25 (26) 16 (33)
Abbreviations: AFB, acid-fast bacilli; CFUs, colony-forming units; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.
aData represent no. (%) of patients unless otherwise specified.
bTime to positivity in liquid culture medium (mycobacteria growth indicator tube [MGIT] 960).
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to positivity in liquid culture medium. We suggest that, like 
AFB smear, time to positivity is another risk factor for trans-
mission, as it has been inversely associated, with enhanced tu-
berculosis transmission in household contacts [24]. Second, 
none of the host factors we studied was associated with aerosol 
positivity in the adjusted analysis, although it is important to 
emphasize that we did not evaluate other factors that could fa-
cilitate aerosolization, such as 24-hour cough-frequency [25] or 
Table 2.  Unadjusted Analysis of Characteristics Associated With Cough-Generated Aerosol Cultures From Patients With Pulmonary Tuberculosis 
Characteristica
Patients, No. (%)b
P ValuecAll Patients Aerosol Negative
Aerosol Positive
Low CFU Count 
(1–9 CFUs)
High CFU Count  
(≥10 CFUs)
Total group 233 133 (57) 43 (18) 57 (25) …
Age, median (IQR), y 30 (25–40) 31 (25–39) 31 (25–44) 30 (24–41) .75
Sex      
 Male 151 (65) 85 (56) 28 (18) 38 (25) .94
 Female 82 (35) 48 (59) 15 (18) 19 (23)
BMI,d median (IQR) 19 (17–21) 19 (17–21) 19 (17–20) 19 (17–21) .53
HIV status      
 Infected 64 (30) 40 (63) 14 (22) 10 (15) .20
 Uninfected 153 (70) 85 (56) 27 (18) 41 (27)
Karnofsky performance score      
 50–80 61 (29) 39 (64) 8 (13) 14 (23) .35
 90–100 154 (71) 84 (54) 32 (21) 38 (25)
BCG status      
 Present 147 (70) 88 (60) 25 (17) 34 (23) .36
 Absent/uncertain 62 (30) 31 (50) 15 (24) 16 (26)
Duration of symptoms, median (IQR), wk 12 (8–20) 12 (8–20) 12 (8–16) 12 (8–16) .33
Duration of antibiotic treatment, median (IQR), d 1 (0–3) 2 (1–4) 1 (0–2) 1 (0–2) <.001
Radiographic findings      
 Cavities      
  Yes 150 (72) 87 (58) 24 (16) 39 (26) .37
  No 59 (28) 33 (56) 14 (24) 12 (20)
 Extent of disease     .
  Normal/minimal 19 (9) 13 (68) 5 (26) 1 (5) 24
  Moderately advanced 57 (27) 29 (51) 12 (21) 16 (28)
  Far advanced 133 (64) 78 (59) 21 (16) 34 (25)
Cough parameters      
 Cough strength     .
  Weak 101 (33) 60 (59) 20 (20) 21 (21) 52
  Strong 132 (67) 73 (55) 23 (17) 36 (27)
 Visual analog cough scale score, median (IQR) 5 (4–7) 5 (4–7) 5 (4–7) 5 (4–7) .92
 Peak expiratory flow rate, median (IQR), L/min 240 (160–320) 230 (170–270) 230 (170–230) 280 (200–350) .16
Sputum characteristics      
 Sputum volume, median (IQR), mL 5 (4–10) 5 (3–10) 5 (3–8) 7 (5–13) .03
 Sputum appearance     .
  Salivary/mucosalivary 90 (42) 52 (58) 15 (17) 23 (25) 59
  Purulent/mucopurulent 122 (58) 64 (53) 27 (22) 31 (25)
 AFB smear grade      
  1+ 34 (15) 23 (67) 6 (18) 5 (15) .01
  2+ 47 (20) 35 (74) 7 (15) 5 (11)
  3+ 152 (65) 75 (49) 30 (20) 47 (31)
 Time to sputum culture positivity,e median (IQR), d 6 (4–9) 7 (4–10) 5 (4–8) 5 (3–6) .02 
Abbreviations: AFB, acid-fast bacilli; BCG, bacille Calmette-Guérin; BMI, body mass index; CFU, colony-forming unit; HIV, human immunodeficiency virus; IQR, interquartile range.
aData were missing for age in 2 patients, for body mass index in 23, for HIV status in 18, Karnofsky performance score in 20, BCG status in 27, duration of symptoms in 16, chest radiography 
in 26, sputum volume in 31, AFB smear grade in 2, sputum appearance in 69, and time to sputum culture positivity in 22.
bData represent no. (%) of patients unless otherwise specified.
cP values were estimated using χ2 tests for categorical variables and Kruskal-Wallis tests for numerical variables. 
dCalculated as the weight in kilograms divided by height in meters squared.
eTime to positivity in liquid culture medium (mycobacteria growth indicator tube [MGIT] 960).
Infectiousness in Smear-Positive Patients With Pulmonary Tuberculosis • ofid • 7
forced expiratory volume [26]. Alternatively, it is possible that 
bacterial survival in aerosol samples is modulated by yet un-
known phenotypic or genotypic factors, such as lipid wall con-
tent, as suggested for nontuberculous mycobacteria [27]. Third, 
our results suggest that patients with pulmonary tuberculosis 
with advanced HIV are less likely to produce culturable aerosol 
samples, a finding consistent with transmission studies in this 
population [28]. Finally, cough-generated aerosol samples be-
come rapidly sterile after antituberculous therapy is initiated, at 
a faster rate of decline compared with AFB smear and culture 
[29].
The marked decrease in tuberculosis infectiousness promptly 
after initiation of proper therapy and well before sputum smear 
conversion has been suggested elsewhere [30]. While in high-
incidence settings significant delays in diagnosis and treatment 
initiation lead to continuous tuberculosis transmission [31], in 
low-incidence settings patients with tuberculosis often remain 
under respiratory isolation until either 3 sputum smears be-
come negative or at least 2 weeks of proper tuberculosis therapy 
is provided, despite little evidence to support this recommen-
dation [32]. 
In the seminal studies by Riley and colleagues [6, 7], tuber-
culosis transmission to guinea pigs ceased almost immediately 
after tuberculosis therapy. Furthermore, transmission in tuber-
culosis wards in Peru occurred only from patients with unsus-
pected drug-resistant tuberculosis or from those with delayed 
tuberculosis treatment initiation [33]. We posit that effective 
therapy could decrease tuberculosis infectiousness in 2 ways: 
(1) by decreasing bacterial burden and (2) by impairing the in-
nate ability of the mycobacteria to survive in aerosol samples. 
If our results are confirmed by future studies, it could have 
consequential implications for infection control policies. In 
fact, the concept that nosocomial tuberculosis transmission is 
driven mainly by unsuspected or untreated tuberculosis cases 
Table 3. Logistic Regression Model of Factors Associated With Growth of Mycobacterium tuberculosis in Cultures of Cough-Generated Aerosol Samplesa
Variable Samples, No. OR (95% CI) P Value
Antibiotic treatment durationb 206 1.47 (1.16–1.89) .001
Sputum volumec 197 1.01 (.96–1.06) .64
Cavitations on chest radiograph 150 0.59 (.27–1.29) .19
Time to sputum culture positivity, dd 214 0.98 (.92–1.03) .43
Sputum AFB smear grade    
 3+ 34 1.55 (.50–4.83) .45
 2+ 57 0.43 (.11–1.72)
 1+ 152 Reference standard  
HIV infection 64 1.61 (.39–3.76) .27
Abbreviations: AFB, acid-fast bacilli; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio.
aComparing samples from aerosol-positive (high and low aerosol colony-forming unit counts) versus aerosol-negative patients.
bEstimated per 1-day decrease in antibiotic use.
cEstimated per 1-mL increase in sputum volume.
dEstimated per 1-day increase in time to positivity for culture in liquid medium (mycobacteria growth indicator tube [MGIT] 960).
Table 4. Cough-Generated Aerosol Results According to Sputum Smear Microscopy Grade
Result All Patients AFB 1+ (n = 34) AFB 2+ (n = 47) AFB 3+ (n = 152) P Value
Time to sputum culture positivity, da (n = 214) (n = 30) (n = 42) (n = 142)  
 Median (IQR) 6 (4–9) 10 (7–13) 8 (7–10) 5 (3–6) .02
 Mean (SD) 7.2 (5.7) 10.2 (4.9) 8.9 (4.1) 6.1 (6.0)
 Range 1–42 2–20 1–27 1–42
Aerosol negative, No. (%) 133 (57) 23 (68) 35 (74) 75 (49) .004
Aerosol positive, No. (%) 100 (43) 11 (32) 12 (26) 77 (51)
Aerosol CFU Count, CFUs      
 All patients      
  Median (IQR) 0 (0–8) 0 (0–2) 0 (0–1) 1 (0–19) .001
  Mean (SD) 18.8 (63.9) 12.9 (57.0) 4.0 (11.4) 24.7 (73.5)
  Range 0–710 0–333 0–57 0–710
 Aerosol-positive patients (n = 100) (n = 11) (n = 12) (n = 77)  
  Median (IQR) 16 (4–36) 8 (2–27) 6 (3–28) 19 (5–49) .12
  Mean (SD) 44.9 (92.2) 40 (97.8) 15.6 (18.6) 48.7 (97.8)
  Range 1–710 1–333 1–57 1–710
Abbreviations: AFB, acid-fast bacilli; IQR, interquartile range; SD, standard deviation.
aTime to positivity in liquid culture medium (mycobacteria growth indicator tube [MGIT] 960).
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is the basis of the find cases actively, separate safely and treat 
effectively  strategy that aims to control tuberculosis spread 
in congregate settings by actively identifying unsuspected tu-
berculosis cases and prompt initiating tuberculosis therapy in 
high-incidence settings [34].
In the current study, 57% of patients with pulmonary tuber-
culosis did not produce culturable M.  tuberculosis in aerosol 
samples, despite evidence of culture-positive disease in sputum. 
Nevertheless, studies using polymerase chain reaction (PCR) 
have identified M.  tuberculosis in aerosol samples from close 
to 90% of patients with tuberculosis [35, 36]. The mechanisms 
behind the apparent improved yield of PCR compared with 
culture in aerosol samples is unclear; a possible explanation 
is that, when exposed to the stresses of aerosolization and air-
borne desiccation, some tuberculous bacilli may survive in 
a nonculturable state, as observed in other bacteria [37]. It is 
also likely that PCR is detecting nonviable bacilli that may be 
aerosolized from the respiratory tract but unable to replicate 
and cause disease in the exposed host after inhalation. 
In our previous studies linking aerosol results to infection 
outcomes, household contacts of aerosol-negative patients had 
higher rates of tuberculin skin test positivity than community 
controls [12, 14], suggesting that aerosol-negative patients with 
tuberculosis may still transmit M. tuberculosis. However, when 
compared with infected contacts of aerosol-positive tubercu-
losis cases, aerosol negative contacts had significantly lower 
interferon gamma release assay responses and mostly have 
culture-negative tuberculosis disease during follow-up [12]. 
Taken together, these data suggest that measurements from 
cough-generated aerosol samples identify a subgroup of high-
risk patients with pulmonary tuberculosis who transmit qual-
itatively different tuberculosis infection to their close contacts, 
with clustering of secondary tuberculosis cases around the 
aerosol-positive phenotype.
Our study has limitations. First, because we included sputum 
AFB-positive patients with mostly advanced radiographic tu-
berculosis disease, our results might not be generalizable to 
other important groups, such as those with smear-negative or 
subclinical tuberculosis. Second, other factors, such as time of 
contact and proximity to the index tuberculosis case patient, are 
also important to assess infectiousness [38]. Third, the data on 
CASS as a marker of infectiousness are based on only 2 house-
hold contact studies. Fourth, we performed aerosol sampling 
at only 1 point, which could lead to exposure misclassification. 
Fifth, most of our cohort were already receiving tuberculosis 
treatment at the time of CASS collection. Finally, the CASS 
device in its present form is designed as a research tool rather 
than a point-of-care device, which could limit its applicability 
in resourced-constrained settings. Although it would presum-
ably be advantageous to have a more rapid signal (such as PCR) 
indicating the presence of M. tuberculosis in biological aerosols 
[36], such a test may not be able to discriminate the viability of 
the detected DNA.
In conclusion, we found that only a minority of sputum 
smear–positive patients with tuberculosis produce culturable 
M.  tuberculosis in cough-generated aerosol samples. Aerosol 
production is only partially related to measures of bacil-
lary burden, such as AFB smear grade or time to positivity in 
liquid medium. Antituberculous therapy seems to rapidly de-
crease bacterial viability in aerosol samples. Future mechanistic 
studies should further evaluate the role of the aerosol-positive 
phenotype in tuberculosis transmission, and the efficacy and 
cost-effectiveness of interventions aimed at targeting preventive 
therapy based on aerosol CFU counts rather than sputum AFB 
smear results as currently recommended.
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